Mga Batayang Estadistika
| CIK | 1235007 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Endocyte, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 14, 2019 |
ECYT / Endocyte, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Endocyte, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2018 Date of Event Which Requires Filing |
|
| December 31, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-35050 Endocyte, Inc. (Exact name of registrant as specified in its chart |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
As filed with the Securities and Exchange Commission on December 21, 2018 Registration No. |
|
| December 21, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 17, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inc |
|
| December 21, 2018 |
Amended and Restated Certificate of Incorporation of Endocyte, Inc., effective December 21, 2018 Exhibit 3.1 Amended and Restated Certificate of Incorporation of Endocyte, Inc. 1. The name of the corporation is “Endocyte, Inc.” (the “Corporation”). 2. The address of the Corporation’s registered office is Corporation Service Company, 251 Little Falls Drive, New Castle County Wilmington, Delaware 19808. The Corporation Service Company is the Corporation’s registered agent at that address. 3. Th |
|
| December 21, 2018 |
Amended and Restated Bylaws of Endocyte, Inc., effective December 21, 2018 Exhibit 3.2 BY-LAWS OF ENDOCYTE, INC. (the “Corporation”) 1. MEETINGS OF STOCKHOLDERS. 1.1 Annual Meeting. The annual meeting of stockholders shall be held on such date and at such time as shall be designated from time to time by the board of directors (the “Board”) and stated in the notice of the meeting or waiver of notice thereof; except that no annual meeting need be held if all actions, inclu |
|
| December 21, 2018 |
Form of Amendment to Change in Control and Severance Agreement Exhibit 10.2 AMENDMENT TO CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amendment to Change in Control and Severance Agreement (the “Amendment”) is made and entered into by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Employee”), effective , 2018, to amend the Change in Control and Severance Agreement (“Agreement”) made and entered into effective as of , 20 , by and b |
|
| December 20, 2018 |
As filed with the Securities and Exchange Commission on December 20, 2018 Registration No. |
|
| December 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 14, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inc |
|
| December 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted b |
|
| December 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inc |
|
| November 16, 2018 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted b |
|
| November 8, 2018 |
ECYT / Endocyte, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (E |
|
| November 7, 2018 |
Exhibit 99.1 Investor Contact: Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Provides Third Quarter 2018 Financial Results and Operational Update -Entered into agreement and plan of merger with Novartis AG for $2.1Billion- WEST LAFAYETTE, Ind., November 7th, 2018 (GLOBE NEWSWIRE) - Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical comp |
|
| November 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inco |
|
| November 6, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| November 5, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| November 1, 2018 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Endocyte, Inc. and further agree that this Joint Filing Agreement be included as an Exhibi |
|
| November 1, 2018 |
ECYT / Endocyte, Inc. / Magnetar Financial LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* ENDOCYTE, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29269A102 (CUSIP Number of Class of Securities) Alec N. Litowitz Magnetar Capital LLC 1603 Orrington Ave. Evanston, Illinois 60201 (847) 905-4400 (Name |
|
| October 31, 2018 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted b |
|
| October 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| October 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| October 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| October 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant o Filed by a Party other than the Registrant x Check the appropriate box: o Preliminary Proxy Statement o Confide |
|
| October 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted b |
|
| October 18, 2018 |
Amended and Restated Bylaws of Endocyte, Inc., effective October 17, 2018 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ENDOCYTE, INC. (as amended and restated effective as of October 17, 2018) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 6 2.6 QU |
|
| October 18, 2018 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of October 17, 2018, among NOVARTIS AG, EDINBURGH MERGER CORPORATION and ENDOCYTE, INC. TABLE OF CONTENTS Page ARTICLE I The Merger SECTION 1.01. The Merger 2 SECTION 1.02. Closing 2 SECTION 1.03. Effective Time 2 SECTION 1.04. Effects of Merger 2 SECTION 1.05. Certificate of Incorporation and Bylaws 2 SECTION 1.06. Directors and Officers 3 ARTICLE |
|
| October 18, 2018 |
Exhibit 99.1 NEWS RELEASE Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., October 18, 2018 (GLOBE NEWSWIRE) — Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics f |
|
| October 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 17, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inco |
|
| October 18, 2018 |
Amended and Restated Bylaws of Endocyte, Inc., effective October 17, 2018 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ENDOCYTE, INC. (as amended and restated effective as of October 17, 2018) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETINGS 6 2.6 QU |
|
| October 18, 2018 |
DEFA14A 1 a18-3691018k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 17, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Comm |
|
| October 18, 2018 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of October 17, 2018, among NOVARTIS AG, EDINBURGH MERGER CORPORATION and ENDOCYTE, INC. TABLE OF CONTENTS Page ARTICLE I The Merger SECTION 1.01. The Merger 2 SECTION 1.02. Closing 2 SECTION 1.03. Effective Time 2 SECTION 1.04. Effects of Merger 2 SECTION 1.05. Certificate of Incorporation and Bylaws 2 SECTION 1.06. Directors and Officers 3 ARTICLE |
|
| October 18, 2018 |
Press Release, dated October 18, 2018 Exhibit 99.1 NEWS RELEASE Endocyte Enters Into Agreement to be Acquired by Novartis AG for $2.1 Billion Novartis to acquire Endocyte for $24 per fully diluted share in cash PSMA-617 to enhance Novartis’ industry-leading radio-ligand therapy platform WEST LAFAYETTE, Ind., October 18, 2018 (GLOBE NEWSWIRE) — Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics f |
|
| September 12, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 11, 2018 ENDOCYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction of (Commission (I.R.S. Employer in |
|
| September 12, 2018 |
Exhibit 1.1 9,459,460 Shares Endocyte, Inc. UNDERWRITING AGREEMENT September 11, 2018 JEFFERIES LLC WELLS FARGO SECURITIES, LLC RBC CAPITAL MARKETS, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Wells Fargo Securities, LLC 375 Park Avenue, 4th Floor New York, New York 10152 c/o RBC Capital Markets, LLC 200 Vesey Street New York |
|
| September 12, 2018 |
Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| September 10, 2018 |
424B5 1 a2236563z424b5.htm PRELIMINARY PROSPECTUS SUPPLEMENT Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-227261 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus ar |
|
| September 10, 2018 |
ECYT / Endocyte, Inc. REGISTRATION STATEMENT ON FORM S-3ASR S-3ASR 1 a2236562zs-3asr.htm REGISTRATION STATEMENT ON FORM S-3ASR Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on September 10, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENDOCYTE, INC. ( |
|
| September 10, 2018 |
Exhibit 4.7 ENDOCYTE, INC. TO [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities Endocyte, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of [ ] Trust Indenture Act Section Indenture Section §310 (a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 §311 (a) 613 (b) 613 §312 (a) 701, 702(a) (b) 702(b) (c) 702(c) |
|
| September 10, 2018 |
Form of Subordinated Indenture Exhibit 4.8 ENDOCYTE, INC. TO [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities Endocyte, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of [ ] Trust Indenture Act Section Indenture Section §310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 §311(a) 613 (b) 613 §312(a) 701, 702(a) (b) 702(b) (c) 702 |
|
| September 10, 2018 |
Computation of Ratio of Earnings to Fixed Charges Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (dollars in thousands) Fiscal Year Ended December 31, Six Months Ended June 30, 2013 2014 2015 2016 2017 2018 Fixed Charges Interest expense on indebtedness $ — $ — $ — $ — $ — $ — Non-cash interest expense and other — — — — — — Interest expense on portion of rent expense representative of interest 113 125 106 107 1 |
|
| September 10, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 f8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 10, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I. |
|
| September 10, 2018 |
Exhibit 99.1 Investor Contact: Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200 [email protected] NEWS RELEASE Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS) Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full appr |
|
| August 1, 2018 |
Exhibit 10.8 ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN TIME-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT This Award Agreement (“Award Agreement”), dated as of , 20, is by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Participant”). Unless otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the “Plan”), shall have the same defined |
|
| August 1, 2018 |
Exhibit 10.6 ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN TIME-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT This Award Agreement (“Award Agreement”), dated as of , 20, is by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Participant”). Unless otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the “Plan”), shall have the same defined |
|
| August 1, 2018 |
Exhibit 10.4 ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN TIME-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT This Award Agreement (“Award Agreement”), dated as of , 20, is by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Participant”). Unless otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the “Plan”), shall have the same defined |
|
| August 1, 2018 |
Exhibit 10.9 ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT This Award Agreement (“Award Agreement”), dated as of , 20, is by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Optionee”). Unless otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the “Plan”), shall have the same defined meanings in this Award |
|
| August 1, 2018 |
Exhibit 10.1 FIFTH AMENDMENT TO OFFICE LEASE THIS FIFTH AMENDMENT TO OFFICE LEASE (this “Amendment”) is made and entered into as of the 29th day of May, 2018, by and between TEMPUS ONE COLLEGE PARK LLC (“Landlord”), as successor in interest to ZELLER MANAGEMENT CORPORATION, as agent for Owner (“Original Landlord”), and ENDOCYTE, INC. (“Tenant”). RECITALS WHEREAS, on May 30, 2008, Original Landlord |
|
| August 1, 2018 |
Second Amendment of Lease dated June 14, 2018 between Endocyte, Inc. and Purdue Research Foundation. Exhibit 10.2 PURDUE TECHNOLOGY CENTER 3000 Kent Avenue West Lafayette, Indiana 47906 SECOND AMENDMENT AND EXTENSION OF LEASE THIS SECOND AMENDMENT AND EXTENSION OF LEASE is made this 14th day of June, 2018 by and between PURDUE RESEARCH FOUNDATION (“Landlord”), an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 246), and ENDOCYTE (“ |
|
| August 1, 2018 |
ECYT / Endocyte, Inc. 10-Q (Quarterly Report) 10-Q 1 ecyt-20180630x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| August 1, 2018 |
Exhibit 10.7 ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT This Award Agreement (“Award Agreement”), dated as of , 20, is by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Optionee”). Unless otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the “Plan”), shall have the same defined meanings in this Award |
|
| August 1, 2018 |
Exhibit 10.5 ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT This Award Agreement (“Award Agreement”), dated as of , 20, is by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Optionee”). Unless otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the “Plan”), shall have the same defined meanings in this Award |
|
| July 31, 2018 |
Exhibit 99.1 Investor Contact: Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Provides Second Quarter 2018 Financial Results and Operational Update -Initiated phase 3 VISION study of 177Lu-PSMA-617 in mCRPC- -Secured commercial supply of no-carrier-added Lutetium-177 through 2035- -Investigational new drug (IND) filing for EC17/CAR T-ce |
|
| July 31, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 31, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpo |
|
| July 11, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 5, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpor |
|
| July 11, 2018 |
Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| July 11, 2018 |
EX-99.1 3 ex-99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177 – Strategic Partnership Supports Commercialization Beyond Ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 – West Lafayette, IN., and Garching, Germany, Jul. 9, 2018 – Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM), a specialized |
|
| May 9, 2018 |
ECYT / Endocyte, Inc. 10-Q (Quarterly Report) 10-Q 1 ecyt-20180331x10q.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numb |
|
| May 9, 2018 |
EX-10.1 2 ecyt-20180331ex10194b733.htm EX-10.1 Exhibit 10.1 FOURTH AMENDMENT TO OFFICE LEASE THIS FOURTH AMENDMENT TO OFFICE LEASE (this “Amendment”) is made and entered into as of the 26th day of January, 2018, by and between TEMPUS ONE COLLEGE PARK LLC, an Arkansas limited liability company (“Landlord”), as successor in interest to ZELLER MANAGEMENT CORPORATION, as agent for Owner (“Original Lan |
|
| May 9, 2018 |
Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Provides First Quarter 2018 Financial Results and Operational Update – Recently Updated Phase 2 Data on 177Lu-PSMA-617 Published in The Lancet Oncology Favorable to Preliminary Data Presented at 2017 ESMO Congress – – Positive End of Phase 2 FDA Meeting Set Stage for |
|
| May 9, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 3, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpora |
|
| March 23, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| March 23, 2018 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 15, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorp |
|
| March 15, 2018 |
Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments –Dawn Svoronos, Former President of Merck’s Europe/Canada Region, Brings Significant Commercial Leadership and Board Experience – West Lafayette, Ind., Mar. 15, 2018 |
|
| March 12, 2018 |
ECYT / Endocyte, Inc. / Venrock Healthcare Capital Partners Ii, L.p. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Endocyte, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29269A102 (CUSIP Number) February 28, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| March 2, 2018 |
8-K 1 f8-k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2018 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R |
|
| March 2, 2018 |
EX-99.1 2 ex-99d1.htm EX-99.1 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors –Patrick Machado, Co-founder and Former Chief Business and Financial Officer of Medivation, Brings Significant Experience in Building Value in the Prostate Cancer Space – West Lafay |
|
| March 1, 2018 |
ECYT / Endocyte, Inc. / Moll Peter - PETER MOLL 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Endocyte, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29269A102 (CUSIP Number) September 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 28, 2018 |
ecytS8POS As filed with the Securities and Exchange Commission on February 28, 2018 Registration No. |
|
| February 28, 2018 |
S-8 1 s-8.htm S-8 As filed with the Securities and Exchange Commission on February 28, 2018 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENDOCYTE, INC. (Exact name of registrant as specified in its charter) Delaware 35-1969-140 (State or other jurisdiction of (I.R.S. Employer incorpora |
|
| February 28, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 a18-711038k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2018 ENDOCYTE, INC. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction of (Commi |
|
| February 28, 2018 |
EX-1.1 2 a18-71103ex1d1.htm EX-1.1 Exhibit 1.1 17,857,143 Endocyte, Inc. UNDERWRITING AGREEMENT February 28, 2018 JEFFERIES LLC WELLS FARGO SECURITIES, LLC DEUTSCHE BANK SECURITIES INC. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Wells Fargo Securities, LLC 375 Park Avenue, 4th Floor New York, New York 10152 c/o Deutsche Bank Sec |
|
| February 28, 2018 |
17,857,143 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220920 PROSPECTUS SUPPLEMENT (To Prospectus dated October 24, 2017) 17,857,143 Shares Common Stock We are offering 17,857,143 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Market under the symbol "ECYT". On February 27, 2018, t |
|
| February 28, 2018 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-220920 The information contained in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the |
|
| February 27, 2018 |
Exhibit 10.19 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| February 27, 2018 |
EX-10.22 5 ecyt-20171231ex102216d99.htm EX-10.22 Exhibit 10.22 FIRST AMENDMENT OF LEASE AGREEMENT THIS AGREEMENT is made and entered into this 10th day of November, 2017, by and between PURDUE RESEARCH FOUNDATION , an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 246), (“Landlord”), and ENDOCYTE (“Tenant”). In consideration of the |
|
| February 27, 2018 |
Exhibit 10.16 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| February 27, 2018 |
ECYT / Endocyte, Inc. 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE |
|
| February 27, 2018 |
chedule of Terms for Change in Control and Severance Agreements with Executive Officers Exhibit 10.26 ENDOCYTE, INC. SCHEDULE OF TERMS FOR CHANGE IN CONTROL AND SEVERANCE AGREEMENTS WITH EXECUTIVE OFFICERS February 2018 Termination without Cause or Resignation for Good Reason, prior to a Change in Control or after 12 months following a Change in Control Termination without Cause or Resignation for Good Reason, within 12 months following a Change in Control Name of Executive Officer D |
|
| February 27, 2018 |
Exhibit 10.13 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| February 26, 2018 |
ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 26, 2018 |
ecytEx991 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Announces Phase 3 VISION Trial and Provides Update on Corporate Strategy and Reports Fourth Quarter and Year End 2017 Financial Results ?Phase 3 VISION Trial Design Finalized for 177Lu-PSMA-617 Following Successful End of Phase 2 Meeting with the FDA ? ?Anno |
|
| February 14, 2018 |
ECYT / Endocyte, Inc. / RA Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tv485684sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ENDOCYTE, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| February 14, 2018 |
ECYT / Endocyte, Inc. / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Endocyte, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2017 Date of Event Which Requires Filing |
|
| January 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Endocyte, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title or Class of Securities) 29269A102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 16, 2017 |
ECYT / Endocyte, Inc. / Partner Fund Management, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Endocyte, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 29269A102 (CUSIP Number) November 6, 2017 Date of Event Which Requires Filing of |
|
| November 16, 2017 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Endocyte, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigne |
|
| November 7, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (E |
|
| November 6, 2017 |
ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 6, 2017 |
ecytEx991 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Third Quarter Financial Results - Plans to Initiate Phase 3 Registration for 177Lu-PSMA-617 Accelerated by Radiomedix Agreement to Transfer Active U.S. Investigational New Drug Application (IND) to Endocyte - - The University of Sydney and ANZUP Canc |
|
| October 20, 2017 |
ENDOCYTE, INC. 3000 Kent Avenue, Suite A1-100 West Lafayette, IN 47906 October 20, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Endocyte, Inc. Registration Statement on Form S-3 File No. 333-220920 Acceleration Request Requested Date: October 24, 2017 Requested Time: 5:00 p.m. Eastern Time Ladies and Gentlemen: Purs |
|
| October 12, 2017 |
Computation of Ratios of Earnings to Fixed Charges Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES (dollars in thousands) Fiscal Year Ended December 31, Six Months Ended June 30, 2012 2013 2014 2015 2016 2017 Fixed Charges: Interest expense on indebtedness $ 555 $ — $ — $ — $ — $ — Non-cash interest expense and other 74 — — — — — Interest expense on portion of rent expense representative of interest 74 113 125 10 |
|
| October 12, 2017 |
As filed with the Securities and Exchange Commission on October 12, 2017 S-3 1 s-3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on October 12, 2017 Registration No. 333‑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENDOCYTE, INC. (Exact name of registrant as specified in its charter) Delaware 35‑1969‑140 (State or other jurisdiction of incorpora |
|
| October 12, 2017 |
ecytCurrentFolioCORRESPAccelRequest Faegre Baker Daniels LLP 600 East 96th Street, Suite 600 Indianapolis, Indiana 46240 Phone +1 317 569 9600 Fax +1 317 569 4800 October 12, 2017 VIA EDGAR Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Endocyte, Inc. |
|
| October 12, 2017 |
Form of Subordinated Indenture Exhibit 4.8 ENDOCYTE, INC. TO [] Trustee INDENTURE Dated as of [] Subordinated Debt Securities Endocyte, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of [] Trust Indenture Act Section Indenture Section §310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 §311(a) 613 (b) 613 §312(a) 701, 702(a) (b) 702(b) (c) 702(c) |
|
| October 12, 2017 |
EX-4.7 2 ex-4d7.htm EX-4.7 Exhibit 4.7 ENDOCYTE, INC. TO [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities Endocyte, Inc. Reconciliation and tie between Trust Indenture Act of 1939 and Indenture, dated as of [ ] Trust Indenture Act Section Indenture Section §310(a) (1) 609 (a) (2) 609 (a) (3) Not Applicable (a) (4) Not Applicable (a) (5) 609 (b) 608, 610 §311(a) 613 (b) 613 §312(a) 701, |
|
| October 12, 2017 |
ECYT / Endocyte, Inc. / Cambridge Isotope Laboratories, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Endocyte, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29269A102 (CUSIP Number) September 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| October 2, 2017 |
EX-99.1 5 ex-99d1.htm EX-99.1 Exhibit 99.1 Investor Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Media Contact: David Schull, Russo Partners, LLC., (212) 845-4271, [email protected] NEWS RELEASE Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer - Tr |
|
| October 2, 2017 |
Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| October 2, 2017 |
Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 29, 2017, by and among Endocyte, Inc., a Delaware corporation (the “Company”), and ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH, a company organized under the laws of Germany (“ABX”). WHEREAS, the Company and ABX are party to tha |
|
| October 2, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2017 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of in |
|
| October 2, 2017 |
EX-4.1 2 ex-4d1.htm EX-4.1 Exhibit 4.1 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE OR OTHER SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD, TRANSFERRED OR ASSIGNED EXCEPT (i) PURSUANT TO REGISTRATIONS THEREOF UNDER SUCH LAWS, OR (ii) IF, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY TO ENDOCYTE, INC., THE PROPOSED TRANSFER MAY BE EFFECTED IN CO |
|
| August 9, 2017 |
Exhibit 10.2 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| August 9, 2017 |
EX-10.1 2 ecyt-20170630ex101acb552.htm EX-10.1 Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exch |
|
| August 9, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact |
|
| August 8, 2017 |
ecytEx991 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update - Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 ? - Nearing Completion of Enrollment of Expansion Phase of EC1169 Trial in Prostate Can |
|
| August 8, 2017 |
Endocyte 8-K (Current Report/Significant Event) ecyt_Current_Folio_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| June 2, 2017 |
EX-99.1 2 ex-99d1.htm EX-99.1 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Announces Clinical Updates for EC1456 and EC1169 - Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients - - Refocusing Efforts on Chimeric Antigen R |
|
| June 2, 2017 |
Material Impairments, Costs Associated with Exit or Disposal Activities ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 10, 2017 |
ecytEx991 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update - Conference Call Today at 8:30 a.m. EDT - West Lafayette, Ind., May 10, 2017 ? Endocyte, Inc. (NASDAQ Global Market: ECYT), a leader in developing targeted small molecule drug |
|
| May 10, 2017 |
Endocyte 8-K (Current Report/Significant Event) ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 10, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact |
|
| May 10, 2017 |
Exhibit 10.3 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| May 10, 2017 |
Exhibit 10.1 CONFIDENTIAL TREATMENT REQUESTED Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 24b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended. Omitted information, marked “[*]” in this Exhibit, has been filed separately with the Securities and Exchange Commission together with such request for |
|
| May 10, 2017 |
Exhibit 10.2 Second Amendment to the Amended and Restated License Agreement made effective on March 1, 2010 between the Purdue Research Foundation and Endocyte, Inc. (“Agreement”) This second amendment (“Amendment”), made and entered effective as of the 1st day of March, 2010 (the “Effective Date”) between Endocyte, Inc., with a place of business at 3000 Kent Avenue, Suite A1-100, West Lafayette, |
|
| May 5, 2017 |
ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 24, 2017 |
ecytCurrent FolioDEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2017 |
ecytCurrent FolioDEF14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 14, 2017 |
ecytS8POS As filed with the Securities and Exchange Commission on March 14, 2017 Registration No. |
|
| March 14, 2017 |
As filed with the Securities and Exchange Commission on March 14, 2017 Registration No. |
|
| March 13, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE |
|
| March 13, 2017 |
Exhibit 10.19 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (this "Agreement") is entered into by and between Endocyte, Inc. ("Endocyte"), and Scot L. Harper, Ph.D. ("Harper") (together, the "Parties") and will become effective on the date that is eight calendar days after Harper has executed and not revoked this Agreement (the "Effective Date"). Recita |
|
| March 13, 2017 |
Exhibit 10.20 ENDOCYTE, INC. SCHEDULE OF TERMS FOR CHANGE IN CONTROL AND SEVERANCE AGREEMENTS WITH EXECUTIVE OFFICERS March 2017 Termination without Cause or Resignation for Good Reason, prior to a Change in Control or after 12 months following a Change in Control Termination without Cause or Resignation for Good Reason, within 12 months following a Change in Control Name of Executive Officer Date |
|
| March 13, 2017 |
Exhibit 10.16 PURDUE TECHNOLOGY CENTER 3000 Kent Avenue West Lafayette, Indiana 47906 EXTENSION OF LEASE THIS EXTENSION OF LEASE is made this first day of December, 2016 by and between PURDUE RESEARCH FOUNDATION (“Landlord”), an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 246), and ENDOCYTE (“Tenant”). Landlord and Tenant have p |
|
| March 10, 2017 |
ecytEx992 Exhibit 99.2 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte and Seattle Children?s Research Institute to Collaborate on Endocyte?s Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules for CAR T-cell Therapies - Collaboration pairs leading SMDC technology with recognized CAR T-cell research expert - - Plans to |
|
| March 10, 2017 |
ecytEx991 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update - Conference Call Today at 8:30 a.m. EST - West Lafayette, Ind., March 10, 2017 ? Endocyte, Inc. (NASDAQ Global Market: ECYT), a leader in developing targete |
|
| March 10, 2017 |
ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 21, 2017 |
ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| February 21, 2017 |
Endocyte Appoints Michael T. Andriole as Chief Financial Officer ecytEx991 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Appoints Michael T. Andriole as Chief Financial Officer West Lafayette, Ind., Feb. 21, 2017- Endocyte, Inc. (NASDAQ Global Market: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized the |
|
| November 9, 2016 |
ecytEx991 Exhibit 99.1 Contact: Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Third Quarter 2016 Financial Results - Confirmed Maximum Dose for EC1169 and Initiated Expansion Phase in Prostate Cancer Patients - - First Confirmed RECIST Partial Response Observed in EC1169 Dose Escalation Reported at European Society for Medical |
|
| November 9, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| November 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (E |
|
| October 20, 2016 |
ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 11, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits ecytCurrentFolio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 11, 2016 |
ecytEx991 Exhibit 99.1 Contact: Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Presents Data on Two Lead Clinical Programs at European Society for Medical Oncology (ESMO) 2016 Congress - Anti-tumor activity demonstrated in dose escalation trials for EC1456 and EC1169 ? West Lafayette, Ind., Oct. 10, 2016 - Endocyte, Inc. (NASDAQ Global |
|
| August 5, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact |
|
| August 4, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 ecyt-20160804x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commis |
|
| August 4, 2016 |
ecytEx991 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Second Quarter 2016 Financial Results - Reached Maximum Tolerated Dose in Twice Weekly Dosing Schedule with EC1456 ? - Initiating EC1456 Expansion Cohort in Targeted Population of Folate Receptor-Positive Non-Small Cell Lung Cancer Patients ? - Data |
|
| June 20, 2016 |
Endocyte Appoints Mike Sherman as President and Chief Executive Officer Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Appoints Mike Sherman as President and Chief Executive Officer West Lafayette, Ind., June 20, 2016 - Endocyte, Inc. (NASDAQ Global Market: ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized ther |
|
| June 20, 2016 |
EXHIBIT 10.1 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (this "Agreement") is entered into by and between Endocyte, Inc. ("Endocyte"), and P. Ron Ellis ("Ellis") (together, the "Parties") and will become effective on the date that is eight days after Ellis has executed and not revoked this Agreement (the ?Effective Date?). Recitals A. Ellis has tende |
|
| June 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| May 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| May 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact |
|
| May 4, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpora |
|
| May 4, 2016 |
Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports First Quarter 2016 Financial Results - Data from Phase 1 Dose Escalation Studies of EC1456 and EC1169 to be Presented at ASCO - - Expansion Phase of Trials in Targeted Patients Expected to Yield Efficacy Data in 2016 - - Promising Preclinical Data Demonstrates |
|
| April 20, 2016 |
8-K 1 v4375228k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 31, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commissi |
|
| April 19, 2016 |
Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Announces Promising Preclinical Data for Application of SMDC Technology in CAR T Cell Therapy in Late-Breaking Abstract at American Association for Cancer Research (AACR) Annual Meeting 2016 ? Poster demonstrates novel approach to a universal T cell overcoming key ch |
|
| April 19, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 19, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| March 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 23, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 9, 2016 |
Endocyte POST-EFFECTIVE AMENDMENT NO. 3 As filed with the Securities and Exchange Commission on March 9, 2016 Registration No. |
|
| March 9, 2016 |
As filed with the Securities and Exchange Commission on March 9, 2016 Registration No. |
|
| March 8, 2016 |
EX-4.3 2 v432293ex4-3.htm EXHIBIT 4.3 Exhibit 4.3 NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. SUBJECT TO SECTION 6 BELOW, NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL |
|
| March 8, 2016 |
Exhibit 10.18 PURDUE TECHNOLOGY CENTER 3000 KENT AVENUE WEST LAFAYETTE, INDIANA 47906 LEASE AGREEMENT THIS LEASE AGREEMENT (the “Lease”) is made and entered into as of this 8th day of December, 2015, by and between PURDUE RESEARCH FOUNDATION (“Landlord”), an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 246), and ENDOCYTE (“Tenant |
|
| March 8, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact name |
|
| March 2, 2016 |
EX-99.1 2 v433241ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Fourth Quarter and Year End 2015 Financial Results and Provides Clinical and Pipeline Update - EC1456 and EC1169 Advance in Phase 1 Dose Escalation Studies - - Expansion Phase of Trials in Targeted Patients Expected to |
|
| March 2, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 2, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpo |
|
| January 5, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 5, 2016 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incor |
|
| November 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (E |
|
| November 3, 2015 |
EX-99.1 2 v423614ex99-1.htm EX-99.1 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Third Quarter 2015 Financial Results and Provides Update on Clinical Progress - Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies - - Conference Call Today at 4:30 p.m. EDT - West Lafayette, Ind., Nov. 3, 2015 |
|
| November 3, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v4236148k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 3, 2015 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission |
|
| September 10, 2015 |
EX-99.1 2 v420028ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Announces Final Overall Survival Results from Phase 2b TARGET Trial in Non-Small Cell Lung Cancer Patients – Supports Folate Receptor (FR) as a Valid Target in Non-Small Cell Lung Cancer (NSCLC) – WEST LAFAYETTE, Ind., Sept.7, |
|
| September 10, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4200288k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 7, 2015 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission |
|
| August 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact |
|
| August 4, 2015 |
Limited Power of Attorney Securities Law Compliance Exhibit 24 Limited Power of Attorney Securities Law Compliance The undersigned, as an officer or director of Endocyte, Inc. |
|
| August 4, 2015 |
Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Endocyte Reports Second Quarter 2015 Financial Results and Provides Update on Clinical Progress - Dose Escalation for EC1456 and EC1169 Advance in Phase 1 Studies - - Final Overall Survival Analysis from TARGET Trial of EC145 in NSCLC to be presented at the World Conference on |
|
| August 4, 2015 |
Endocyte 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2015 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorp |
|
| May 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Endocyte, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title or Class of Securities) 29269A102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| May 18, 2015 |
8-K 1 v4110178k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2015 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS |
|
| May 18, 2015 |
Exhibit 10.1 ENDOCYTE, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made and entered into by and between (?Employee?) and Endocyte, Inc., a Delaware corporation (the ?Company?), effective as of , 2015 (the ?Effective Date?). RECITALS 1. It is possible that the Company could terminate Employee?s employment with the Company and it |
|
| May 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact |
|
| May 7, 2015 |
Endocyte 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2015 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpora |
|
| May 7, 2015 |
Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE: Endocyte Reports First Quarter 2015 Financial Results and Provides Update on Clinical Progress - Dose Escalation for EC1456 and EC1169 Move to Fifth Dosing Cohorts Evaluating Two Schedules for Each Agent ? - Conference Call Today at 4:30 p.m. EDT ? West Lafayette, Ind., May 7 |
|
| April 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| April 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 16, 2015 |
S-8 POS 1 v404470s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on March 16, 2015 Registration No. 333-172121 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-effective amendment no. 2 to Form S-8 registration statement UNDER THE SECURITIES ACT OF 1933 ENDOCYTE, INC. (Exact name of registrant as specified in its charter) Delaware 35-1969-140 (Sta |
|
| March 16, 2015 |
As filed with the Securities and Exchange Commission on March 16, 2015 Registration No. |
|
| March 13, 2015 |
Exhibit 10.25 PURDUE TECHNOLOGY CENTER 3000 kent avenue west lafayette, indiana 47906 EXTENSION OF LEASE THIS EXTENSION OF LEASE is made this 9th day of December, 2014 by and between PURDUE RESEARCH FOUNDATION (“Landlord”), an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 246), and ENDOCYTE (“Tenant”). Landlord and Tenant have pre |
|
| March 13, 2015 |
Exhibit 10.14 CONFIDENTIAL TREATMENT REQUESTED [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 24b-2 of the Securities Exchange Act of 1934, as amended, and Rule 406 of the Securities Act of 1933 |
|
| March 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact name |
|
| March 2, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 2, 2015 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpo |
|
| March 2, 2015 |
EX-99.1 2 v403268ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE: Endocyte Reports Fourth Quarter and Year End 2014 Financial Results and Provides Clinical Update - Dose Escalation Continues for EC1456 and EC1169 as Endocyte Outlines Plans for Expansion of the Trials in Targeted Patients Once Maximum |
|
| February 12, 2015 |
ECYT / Endocyte, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3; Exit Filing)* ENDOCYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to |
|
| November 7, 2014 |
SEPARATION AGREEMENT AND RELEASE OF CLAIMS EX-10.1 2 v392677ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims ("Agreement") is entered into by and between Endocyte, Inc. ("Endocyte"), and David D. Meek ("Meek") (collectively, the "Parties"). Recitals A. Endocyte and Meek are parties to a Change in Control and Severance Agreement ("Severance Agreement"), a copy of |
|
| November 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q 10-Q 1 v39267710q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file nu |
|
| November 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inco |
|
| November 5, 2014 |
Endocyte Reports Third Quarter Financial Results and Provides Clinical Update Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE: Endocyte Reports Third Quarter Financial Results and Provides Clinical Update - Folate-targeted EC1456 with Potent Tubulysin Payload Now at Higher Phase 1 Dose Level than Vintafolide – - Conference Call Today at 4:30 p.m. EST – West Lafayette, Ind., Nov. 5, 2014 – Endocyte, I |
|
| October 1, 2014 |
Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE Phase 2b TARGET Trial Results Show Improved Survival in Adenocarcinoma Non-Small Cell Lung Cancer Patients Treated with Endocyte’s Vintafolide - Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid - - Interim Update of |
|
| October 1, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 27, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| August 8, 2014 |
FOURTH AMENDMENT OF LEASE AGREEMENT Exhibit 10.1 FOURTH AMENDMENT OF LEASE AGREEMENT THIS AGREEMENT is executed in duplicate and effective this 1st day of April, 2014, by and between PURDUE RESEARCH FOUNDATION , an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 25), (“PRF”), and ENDOCYTE (“COMPANY”). In consideration of their mutual promises contained in this Amendme |
|
| August 8, 2014 |
LICENSE AGREEMENT ENDOCYTE, INC PURDUE RESEARCH FOUNDATION OCTOBER 21, 1998 Exhibit 10.2 CONFIDENTIAL TREATMENT REQUESTED [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 24b-2 of the Securities Exchange Act of 1934, as amended, and Rule 406 of the Securities Act of 1933, |
|
| August 8, 2014 |
EX-10.3 4 v384793ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 CONFIDENTIAL TREATMENT REQUESTED [*] = Certain confidential information contained in this document, marked with brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment pursuant to, as applicable, Rule 24b-2 of the Securities Exchange Act of 1934, as amended, an |
|
| August 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact |
|
| July 29, 2014 |
EX-99.1 2 v385058ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] NEWS RELEASE: Endocyte Reports Second Quarter Financial Results and Provides Clinical Update - EC1456 Targeting Potent Tubulysin Payload to Advance in Phase 1 to Dose Similar to Vintafolide– - Conference Call Today at 4:30 p.m. EDT – West Lafayette, |
|
| July 29, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v3850588k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 29, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I. |
|
| June 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 17, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpo |
|
| June 23, 2014 |
Endocyte Regains Worldwide Rights to Vintafolide Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, [email protected] Tony Russo, Ph.D., Russo Partners, (212) 845-4251, [email protected] FOR IMMEDIATE RELEASE: Endocyte Regains Worldwide Rights to Vintafolide West Lafayette, Ind., June 17, 20 |
|
| June 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpo |
|
| June 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 2, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpor |
|
| May 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpor |
|
| May 21, 2014 |
Exhibit 99.1 Contacts: Merck: Media: Ian McConnell +1 908-423-3046 Claire Mulhearn +1 908-423-7425 Investors: Carol Ferguson +1 908-423-4465 Justin Holko +1 908-423-5088 Endocyte: Media: Martina Schwarzkopf, Ph.D., Russo Partners +1 212-845-4292 Tony Russo, Ph.D., Russo Partners, +1 212-845-4251 Investors: Stephanie Ascher, Stern Investor Relations, Inc., +1 212-362-1200 FOR IMMEDIATE RELEASE: Mer |
|
| May 16, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| May 12, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 Form 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exac |
|
| May 12, 2014 |
THIRD AMENDMENT OF LEASE AGREEMENT EXHIBIT 10.1 THIRD AMENDMENT OF LEASE AGREEMENT THIS AGREEMENT is executed in duplicate and effective this 31st day of January, 2014, by and between PURDUE RESEARCH FOUNDATION , an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 25), (“PRF”), and ENDOCYTE (“COMPANY”). In consideration of their mutual promises contained in this Amend |
|
| May 2, 2014 |
EX-99.1 2 v376995ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, [email protected] Tony Russo, Ph.D., Russo Partners, (212) 845-4251, [email protected] FOR IMMEDIATE RELEASE: Endocyte Reports First Quarter Financial |
|
| May 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of incorpora |
|
| May 2, 2014 |
Exhibit 99.2 Contacts: Merck: Media: Ian McConnell +1 908-423-3046 [email protected] Claire Mulhearn +1 908-423-7425 [email protected] Investors: Carol Ferguson +1 908-423-4465 [email protected] Justin Holko +1 908-423-5088 [email protected] Endocyte: Media: Martina Schwarzkopf, Ph.D., Russo Partners +1 212- 845-4292 [email protected] Tony Russo, Ph |
|
| March 31, 2014 |
4,500,000 Shares ENDOCYTE, INC. Common Stock UNDERWRITING AGREEMENT Exhibit 1.1 EXECUTION VERSION 4,500,000 Shares ENDOCYTE, INC. Common Stock UNDERWRITING AGREEMENT March 27, 2014 Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc. As Representatives of the Several Underwriters, c/o Credit Suisse Securities (USA) LLC, Eleven Madison Avenue, New York, N.Y. 10010-3629 c/o Citigroup Global Markets Inc., 388 Greenwich Street, New York, N.Y. 10013 Dear S |
|
| March 31, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v3731858k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commissio |
|
| March 28, 2014 |
424B5 1 d698741d424b5.htm 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) File No. 333-194791 Calculation of Registration Fee Title of securities to be registered Amount to be registered (1) Proposed maximum offering price per share Proposed maximum aggregate offering price Amount of registration fee (1) Common Stock, $.001 par value per share 5,175,000 shares $21.00 $108,675,000 $13,997. |
|
| March 25, 2014 |
Exhibit 99.1 Endocyte Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, [email protected] Tony Russo, Ph.D., Russo Partners, (212) 845-4251, [email protected] Merck Contacts: Media: Ian McConnell, (908) 423-3046 Claire Mulhearn, (908)423-7425 Investors: C |
|
| March 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Defin |
|
| March 25, 2014 |
POS AM As filed with the Securities and Exchange Commission on March 25, 2014 Registration No. |
|
| March 25, 2014 |
EX-12.1 Exhibit 12.1 STATEMENT REGARDING COMPUTATION OF RATIO/DEFICIENCY OF EARNINGS TO FIXED CHARGES (dollars in thousands) Fiscal Year Ended December 31 2009 2010 2011 2012 2013 Fixed charges: Interest expense on indebtedness $ 1,226 $ 904 $ 1,342 $ 555 $ 2 Noncash interest expense and other 210 161 646 74 — Interest expense on portion of rent expense representative of interest 51 53 61 74 — Tot |
|
| March 25, 2014 |
S-3ASR 1 d700701ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 25, 2014 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENDOCYTE, INC. (Exact name of registrant as specified in its charter) Delaware 35-1969-140 (State or other jurisdictio |
|
| March 25, 2014 |
Exhibit 99.2 Endocyte Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, [email protected] Tony Russo, Ph.D., Russo Partners, (212) 845-4251, [email protected] NEWS RELEASE Endocyte Announces Phase 2b TARGET Trial Results Evaluating Vintafolide/Docetaxel C |
|
| March 25, 2014 |
Subject to Completion Preliminary Prospectus Supplement dated March 25, 2014 Table of Contents The information in this prospectus supplement and accompanying prospectus is not complete and may be changed. |
|
| March 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| March 25, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| March 6, 2014 |
As filed with the Securities and Exchange Commission on March 6, 2014 Registration No. |
|
| March 5, 2014 |
PURDUE TECHNOLOGY CENTER 3000 kent avenue west lafayette, indiana 47906 EXTENSION OF LEASE EX-10.21 2 v369266ex10-21.htm EXHIBIT 10.21 Exhibit 10.21 PURDUE TECHNOLOGY CENTER 3000 kent avenue west lafayette, indiana 47906 EXTENSION OF LEASE THIS EXTENSION OF LEASE is made this 20th day of November, 2013 by and between PURDUE RESEARCH FOUNDATION (“Landlord”), an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 246), and ENDO |
|
| March 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (Exact name |
|
| February 24, 2014 |
Endocyte Reports Fourth Quarter and Year End 2013 Financial Results and Provides Business Update Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, [email protected] Tony Russo, Ph.D., Russo Partners, (212) 845-4251, [email protected] FOR IMMEDIATE RELEASE: Endocyte Reports Fourth Quarter and Year End 2013 Financial Results and Provides B |
|
| February 24, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v3694958k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 24, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commi |
|
| February 12, 2014 |
ECYT / Endocyte, Inc. / BB BIOTECH AG - SC 13G/A Passive Investment SC 13G/A United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ENDOCYTE, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29269A102 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing This Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| February 10, 2014 |
EXHIBIT 10.1 ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN TIME-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT This Award Agreement (“Award Agreement”), dated as of , 20, is by and between Endocyte, Inc., a Delaware corporation (the “Company”), and (“Participant”). Unless otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the “Plan”), shall have the same defined |
|
| February 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2014 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inco |
|
| December 23, 2013 |
Up to $60,000,000 of Shares of Common Stock 424b5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-187334 PROSPECTUS SUPPLEMENT (to Prospectus dated April 23, 2013) Up to $60,000,000 of Shares of Common Stock We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the t |
|
| December 23, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 20, 2013 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| December 23, 2013 |
Endocyte, Inc. COMMON STOCK SALES AGREEMENT Exhibit 1.1 EXECUTION VERSION Endocyte, Inc. $60,000,000 COMMON STOCK SALES AGREEMENT December 20, 2013 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Endocyte, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the |
|
| November 8, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35050 ENDOCYTE, INC. (E |
|
| November 8, 2013 |
SECOND AMENDMENT OF LEASE AGREEMENT EX-10.1 2 v358770ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECOND AMENDMENT OF LEASE AGREEMENT THIS AGREEMENT is executed in duplicate and effective this 7th day of July, 2013, by and between PURDUE RESEARCH FOUNDATION , an Indiana corporation (formed and existing under the Indiana Foundation or Holding Companies Act, Acts of 1921, ch. 25), (“PRF”), and ENDOCYTE (“COMPANY”). In consideration of their m |
|
| November 7, 2013 |
8-K 1 v3597448k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 7, 2013 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission |
|
| November 7, 2013 |
Colin Goddard, Ph.D., Joins the Endocyte Board of Directors Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200 Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292 Tony Russo, Ph. D., Russo Partners, (212) 845 4251 NEWS RELEASE Colin Goddard, Ph.D., Joins the Endocyte Board of Directors West Lafayette, Ind., Nov. 7, 2013 – Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company and leader in devel |
|
| November 5, 2013 |
Endocyte Reports Third Quarter 2013 Financial Results and Provides Business Update Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, [email protected] Tony Russo, Ph.D., Russo Partners, (212) 845-4251, [email protected] NEWS RELEASE Endocyte Reports Third Quarter 2013 Financial Results and Provides Business Update - Confere |
|
| November 5, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2013 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of inco |
|
| October 11, 2013 |
Exhibit 99.1 Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected] Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292, [email protected] Tony Russo, Ph.D., Russo Partners, (212) 845-4251, [email protected] NEWS RELEASE Endocyte Announces DSMB Recommendation for Continuation of Vintafolide/Docetaxel Combination |
|
| October 11, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 11, 2013 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| September 26, 2013 |
Regulation FD Disclosure - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 25, 2013 Endocyte, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35050 35-1969-140 (State or other jurisdiction (Commission (I.R.S. Employer of in |
|
| August 9, 2013 |
FIRST AMENDMENT OF LEASE AGREEMENT EX-10.1 3 v351492ex10-1.htm EXHIBIT 10.1 EXHIBIT 10.1 FIRST AMENDMENT OF LEASE AGREEMENT THIS AGREEMENT is executed in duplicate this 17th day of May, 2013, by and between PURDUE RESEARCH FOUNDATION, an Indiana corporation, of Tippecanoe County, Indiana, (“Lessor”), and ENDOCYTE (“Tenant”). In consideration of their mutual promises contained in this Amendment, the parties agree as follows: WHEREAS |
